Emmanuel Lafont

Emmanuel Lafont


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 September 2020 in Journal of Clinical Immunology
Verified
Journal Article
Closed access
PDF file
ELEMMANUEL Lafont
EMMANUEL Lafont
BMBeatriz E. Marciano
Beatriz E. Marciano
NMNizar Mahlaoui
Nizar Mahlaoui
BNBénédicte Neven
Bénédicte Neven
JBJacinta Bustamante
Jacinta Bustamante
DLDavid Lebeaux
David Lebeaux

5 March 2024 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
JPJessica N. Peel
Jessica N. Peel
RYRui Yang
Rui Yang
TVTom Le Voyer
Tom Le Voyer
AGAdrian Gervais
Adrian Gervais
JRJérémie Rosain
Jérémie Rosain
JCJean-Laurent Casanova
Jean-Laurent Casanova
BACKGROUND: Weakly virulent environmental mycobacteria (EM) can cause severe disease in HLA-DRB1*15:02 or 16:02 adults harboring neutralizing anti-IFN-γ autoantibodies (nAIGAs). The overall prevalence of nAIGAs in the general population is unknown, as are the penetrance of nAIGAs in HLA-DRB1*15:02 or 16:02 individuals and the proportion of patients with unexplained, adult-onset EM infections carrying nAIGAs. METHODS: This study analyzed the detection and neutralization of anti-IFN-γ autoantibodies (auto-Abs) from 8,430 healthy individuals of the general population, 257 HLA-DRB1*15:02 or 16:02 carriers, 1,063 patients with autoimmune disease, and 497 patients with unexplained severe disease due to EM. RESULTS: We found that anti-IFN-γ auto-Abs detected in 4,148 of 8,430 healthy individuals (49.2%) from the general population of an unknown HLA-DRB1 genotype were not neutralizing. Moreover, we did not find nAIGAs in 257 individuals carrying HLA-DRB1* 15:02 or 16:02. Additionally, nAIGAs were absent in 1,063 patients with an autoimmune disease. Finally, 7 of 497 patients (1.4%) with unexplained severe disease due to EM harbored nAIGAs. CONCLUSION: These findings suggest that nAIGAs are isolated and that their penetrance in HLA-DRB1*15:02 or 16:02 individuals is low, implying that they may be triggered by rare germline or somatic variants. In contrast, the risk of mycobacterial disease in patients with nAIGAs is high, confirming that these nAIGAs are the cause of EM disease. FUNDING: The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute, the Rockefeller University, the St. Giles Foundation, the National Institutes of Health (NIH) (R01AI095983 and U19AIN1625568), the National Center for Advancing Translational Sciences (NCATS), the NIH Clinical and Translational Science Award (CTSA) program (UL1 TR001866), the French National Research Agency (ANR) under the “Investments for the Future” program (ANR-10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), ANR-GENMSMD (ANR-16-CE17-0005-01), ANR-MAFMACRO (ANR-22-CE92-0008), ANRSECTZ170784, the French Foundation for Medical Research (FRM) (EQU201903007798), the ANRS-COV05, ANR GENVIR (ANR-20-CE93-003), and ANR AI2D (ANR-22-CE15-0046) projects, the ANR-RHU program (ANR-21-RHUS-08-COVIFERON), the European Union’s Horizon 2020 research and innovation program under grant agreement no. 824110 (EASI-genomics), the Square Foundation, Grandir - Fonds de solidarité pour l’enfance, the Fondation du Souffle, the SCOR Corporate Foundation for Science, the Battersea & Bowery Advisory Group, William E. Ford, General Atlantic’s Chairman and Chief Executive Officer, Gabriel Caillaux, General Atlantic’s Co-President, Managing Director, and Head of business in EMEA, and the General Atlantic Foundation, Institut National de la Santé et de la Recherche Médicale (INSERM) and of Paris Cité University. JR was supported by the INSERM PhD program for doctors of pharmacy (poste d’accueil INSERM). JR and TLV were supported by the Bettencourt-Schueller Foundation and the MD-PhD program of the Imagine Institute. MO was supported by the David Rockefeller Graduate Program, the Funai Foundation for Information Technology (FFIT), the Honjo International Scholarship Foundation (HISF), and the New York Hideyo Noguchi Memorial Society (HNMS).

1 December 2016 in La Revue de Médecine Interne
Verified
Journal Article
Closed access
GRG. Rossi
G. Rossi
ELEMMANUEL Lafont
EMMANUEL Lafont
LGL. Gasperini
L. Gasperini
SDS. Dokmak
S. Dokmak
MRM. Ronot
M. Ronot
ALA. Lefort
A. Lefort

9 June 2020 in Transplant Infectious Disease
Verified
Journal Article
Closed access
PDF file
ELEMMANUEL Lafont
EMMANUEL Lafont
OROlivier Roux
Olivier Roux
VLVictoire Dor de Lastours
Victoire Dor de Lastours
SDSafi Dokmak
Safi Dokmak
VLVéronique Leflon
Véronique Leflon
ALAgnès Lefort
Agnès Lefort

1 December 2019 in La Revue de Médecine Interne
Verified
Journal Article
Closed access
SCS. Cattan
S. Cattan
GTG. Thizy
G. Thizy
AMA. Michon
A. Michon
JAJ.-B. Arlet
J.-B. Arlet
FLF. Lanternier
F. Lanternier
ELEMMANUEL Lafont
EMMANUEL Lafont

14 October 2023 in Chest
Verified
Journal Article
Closed access
GTGuillaume Thizy
Guillaume Thizy
AFAdrien Flahault
Adrien Flahault
ASAnne Scemla
Anne Scemla
OROlivier Roux
Olivier Roux
SJSophie Jarraud
Sophie Jarraud
ELEMMANUEL Lafont
EMMANUEL Lafont